Comparative Pharmacology
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UTICILLIN VK versus VEETIDS 250.
UTICILLIN VK vs VEETIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
VEETIDS '250' is an oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
250 mg orally every 8 hours for 7-10 days
None Documented
None Documented
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
2-3 hours in adults with normal renal function; prolonged to 24-40 hours in anuria/end-stage renal disease, requiring dose adjustment.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Primarily renal (≥90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic